Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Anticonvulsants Market?

There has been consistent growth in the size of the anticonvulsants market in the past few years. It is forecasted to expand from $18.85 billion in 2024 to $19.25 billion in 2025, with a compound annual growth rate (CAGR) of 2.1%. Factors contributing to this growth during the historic period include the increasing occurrence of epilepsy, improvements in diagnostic abilities, wider range of indications, emphasis on tailored medicine, and heightened awareness and education.

Predictions indicate a consistent expansion of the anticonvulsants market size in the approaching years, culminating in a worth of $22.29 billion in 2029. This will occur at a compound annual growth rate (CAGR) of 3.7%. The expected growth during the forecast period can be chalked up to a persistent surge in epilepsy incidents, broader applications in neuropsychiatry, the emergence of new anticonvulsant agents, and an intensified focus on mental health within global health initiatives. Noteworthy trends set to shape the forecast period encompass pediatric applications and formulations, a shift toward extended-release formulas, the rising popularity of generic versions, digital health solution integrations, and studies on neuroprotective impact.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10682&type=smp

Which Factor Is Shaping The Future Of The Anticonvulsants Market?

The anticonvulsants market is expected to see a significant growth driven by the increased prevalence of epilepsy. This common brain disorder often triggers seizures and can affect people of all ages. Anticonvulsants serve as medicine to assist in controlling seizures in those suffering from epilepsy. While these medications help to manage symptoms of epilepsy by inhibiting the abnormal brain activity that instigates seizures, they are not a definitive cure for the condition. The World Health Organization, a Switzerland-based agency in charge of public health under the United Nations, stated in February 2023 that an estimated 5 million people are diagnosed with epilepsy yearly on a global level. An estimated 49 per 0.1 million individuals in high-income countries are given a diagnosis of epilepsy each year, with the number rising to 139 per 0.1 million in low and middle-income countries. Thus, the escalating occurrence of epilepsy globally is contributing to the growth of the anticonvulsants market.

What Is The Segment-Wise Breakdown Of The Anticonvulsants Market?

The anticonvulsants market covered in this report is segmented –

1) By Type: Pyrimidinediones, Benzodiazepines, Fructose Derivatives, Aromatic Allylic Alcohols, Valproylamides, Carboxamides, Bromides, Other Types

2) By Drug Generation: First Generation, Second Generation, Third Generation

3) By Dosage: Capsule, Tablet, Cream, Liquid, Rectal Gel, Other Dosages

4) By Application: Migraine, Epilepsy, Neuropathic Pain, Anxiety, Fibromyalgia, Bipolar Disorder, Borderline Personality Disorder

5) By End-User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Pyrimidinediones: Stiripentol

2) By Benzodiazepines: Clonazepam, Diazepam, Lorazepam

3) By Fructose Derivatives: S-licarbazepine, Other Fructose Derivatives

4) By Aromatic Allylic Alcohols: Felbamate, Other Aromatic Allylic Alcohols

5) By Valproylamides: Valproic Acid, Divalproex Sodium

6) By Carboxamides: Lamotrigine, Other Carboxamides

7) By Bromides: Potassium Bromide, Sodium Bromide

8) By Other Types: Topiramate, Zonisamide, Ethosuximide

Which Trends Are Redefining The Future Landscape Of The Anticonvulsants Industry?

The growing trend of product innovation is apparent in the anticonvulsants market, with major firms directing their efforts towards the creation of pioneering products to solidify their market presence and edge out competition. For example, Lupin Limited, a pharmaceutical company based in India, introduced a new drug application, Rufinamide tablets USP, with dosages of 200mg and 400mg, in December 2022. This anticonvulsant medicine, Rufinamide, is used alongside other drugs to manage seizures in individuals diagnosed with a severe epilepsy version known as Lennox-Gastaut syndrome. This condition, which originates during childhood, triggers various types of seizures, behavioral issues, and developmental lags in a person.

Which Companies Hold The Largest Market Share In The Anticonvulsants Sector?

Major companies operating in the anticonvulsants market include Eisai Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services Inc ., Novartis AG, Jazz Pharmaceuticals Inc., UCB SA, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Sanofi SA, Zydus Lifesciences Ltd., Lupin Limited, Ratiopharm Group, Kannalife Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals plc, AstraZeneca plc, Glenmark Pharmaceuticals Limited, Laurus Labs Limited, Biocon Limited, Recordati S.p.A., Neurocrine Biosciences Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anticonvulsants-global-market-report

How Does Regional Performance Compare Across The Anticonvulsants Industry?

North America was the largest region in the anticonvulsants market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global anticonvulsants market report during the forecast period. The regions covered in the anticonvulsants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10682&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model